US-Listed Biological Products, (No Diagnostic Substances) — EBITDA Margin Percentiles
Population: 44 US-listed companies (SIC 2836), most recent complete fiscal year per filer; fiscal year ends to .
| 10th percentile | -473.2% |
|---|
| 25th percentile | -249.7% |
|---|
| Median | -147.3% |
|---|
| 75th percentile | 8.9% |
|---|
| 90th percentile | 37.5% |
|---|
| Mean | — |
|---|
| Minimum | -869.9% |
|---|
| Maximum | 42.8% |
|---|
Methodology & sources
EBITDA margin = (operating income + depreciation & amortization) / revenue, all values as filed; computed in SQL per company, then percentiles.
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, as of .
Scope: {"source": "SEC EDGAR (XBRL, as-filed); Summe, Division, percentile_cont in Postgres", "ebitda_semantics": "EBITDA GERECHNET als oi + D&A — kein adjusted EBITDA"}
Evidence samples
Query this live via API/MCP (template peer_ebitda_margin_percentiles); terms: /nutzung. Cite as: FACTANKER, https://factanker.com/industries/sic-2836/ebitda-margin